PGG glucan(PGG glucan) - 药物靶点：CD11b x CD32A_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Betafectin、Imprime、odetiglucan

+ [4]

靶点

CD11b x CD32A

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症

晚期非小细胞肺癌KRAS 野生型结直肠癌皮肤黑色素瘤+ [2]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

Hibercell, Inc.初创企业

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 PGG glucan 相关的临床试验

NCT05484011 / Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

Hibercell, Inc.初创企业

[+1]

NCT05159778 / Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

Hibercell, Inc.初创企业

[+1]

CTRI/2021/10/037380 / Not yet recruiting临床3期

An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid-19 caused by SARS-COV2 (B-COV)

开始日期2021-10-25

申办/合作机构-

100 项与 PGG glucan 相关的临床结果

登录后查看更多信息

100 项与 PGG glucan 相关的转化医学

登录后查看更多信息

100 项与 PGG glucan 相关的专利（医药）

登录后查看更多信息

264

项与 PGG glucan 相关的文献（医药）

2024-10-01·Small

Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization

Article

作者: Peng, Cheng ; Wang, Hai Yang ; Zhu, Zi Jia ; Zu, Hong Lin ; Zhou, Wen Hu ; Wang, Qing Shan ; Yao, Ye ; Yue, Jie ; Zhuang, Pei Pei ; Peng, Chao ; Peng, Ying

Abstract:

Abdominal aortic aneurysm (AAA) represents a critical cardiovascular condition characterized by localized dilation of the abdominal aorta, carrying a significant risk of rupture and mortality. Current treatment options are limited, necessitating novel therapeutic approaches. This study investigates the potential of a pioneering nanodrug delivery system, RAP@PFB, in mitigating AAA progression. RAP@PFB integrates pentagalloyl glucose (PGG) and rapamycin (RAP) within a metal–organic‐framework (MOF) structure through a facile assembly process, ensuring remarkable drug loading capacity and colloidal stability. The synergistic effects of PGG, a polyphenolic antioxidant, and RAP, an mTOR inhibitor, collectively regulate key players in AAA pathogenesis, such as macrophages and smooth muscle cells (SMCs). In macrophages, RAP@PFB efficiently scavenges various free radicals, suppresses inflammation, and promotes M1‐to‐M2 phenotype repolarization. In SMCs, it inhibits apoptosis and calcification, thereby stabilizing the extracellular matrix and reducing the risk of AAA rupture. Administered intravenously, RAP@PFB exhibits effective accumulation at the AAA site, demonstrating robust efficacy in reducing AAA progression through multiple mechanisms. Moreover, RAP@PFB demonstrates favorable biosafety profiles, supporting its potential translation into clinical applications for AAA therapy.

2024-05-01·International journal of biological macromolecules

Discovery of a botanical compound as a broad-spectrum inhibitor against gut microbial β-glucuronidases from the Tibetan medicine Rhodiola crenulata

Article

作者: Hou, Xu-Dong ; Sun, Jian-Ming ; Ge, Guang-Bo ; Zhang, Shou-De ; Huang, Jian ; Ma, Li-Juan ; Zhang, Ya-Ni ; Guo, Zhao-Bin ; Zhu, Guang-Hao ; Hou, Jie ; Chen, Lu

Gut microbial β-glucuronidases (gmβ-GUS) played crucial roles in regulating a variety of endogenous substances and xenobiotics on the circulating level, thus had been recognized as key modulators of drug toxicity and human diseases. Inhibition or inactivation of gmβ-GUS enzymes has become a promising therapeutic strategy to alleviate drug-induced intestinal toxicity. Herein, the Rhodiola crenulata extract (RCE) was found with potent and broad-spectrum inhibition on multiple gmβ-GUS enzymes. Subsequently, the anti-gmβ-GUS activities of the major constituents in RCE were tested and the results showed that 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (PGG) acted as a strong and broad-spectrum inhibitor on multiple gmβ-GUS (including EcGUS, CpGUS, SaGUS, and EeGUS). Inhibition kinetic assays demonstrated that PGG effectively inhibited four gmβ-GUS in a non-competitive manner, with the K_i values ranging from 0.12 μM to 1.29 μM. Docking simulations showed that PGG could tightly bound to the non-catalytic sites of various gmβ-GUS, mainly via hydrogen bonding and aromatic interactions. It was also found that PGG could strongly inhibit the total gmβ-GUS activity in mice feces, with the IC₅₀ value of 1.24 μM. Collectively, our findings revealed that RCE and its constituent PGG could strongly inhibit multiple gmβ-GUS enzymes, suggesting that RCE and PGG could be used for alleviating gmβ-GUS associated enterotoxicity.

2024-04-01·Combinatorial chemistry & high throughput screening

Osteoblast Biospecific Extraction Conjugated with HPLC Analysis for Screening Bone Regeneration Active Components from Moutan Cortex

Article

作者: Jiang, Guorong ; Chen, Wei ; Zhang, Lurong ; Yao, Fei ; Gu, Weiwei ; Zhang Zhu, Ruixian ; Hou, Wenyue ; Xu, Heng ; Liang, Guoqiang

Introduction::

The function of promoting bone regeneration of Moutan Cortex (MC), a traditional Chinese medicine, has been widely known but, the effective components of MC in promoting osteoblast-mediated bone regeneration were still unclear.

Objective::

The method of osteoblast membrane bio-specific extraction conjugated with HPLC analysis was established to screen bone regeneration active components from MC.

Methods::

The fingerprints, washing eluate and desorption eluate of MC extract were analyzed by the established HPLC-DAD method. The established MC3T3-E1 cells membrane chromatography method was used for the bio-specific extraction of MC. The isolated compounds were identified by MS spectrometry. The effects and possible mechanisms of the isolated compounds were evaluated by molecular docking, ALP activity, cell viability by MTT Assay and proteins expression by Western Blot Analysis.

Results::

The active compound responsible for bone regeneration from MC was isolated using the established method of osteoblast membrane bio-specific extraction conjugated with HPLC analysis, and it was identified as 1,2,3,4,6-penta-O-β-galloyl-D-glucose (PGG) by MS spectrometry. It was further demonstrated through molecular docking that PGG could fit well into the functional ALP, BMP2, and Samd1 binding pocket. The proliferation of osteoblasts was promoted, the level of ALP was increased, and the protein expression of BMP2 and Smad1 was increased as shown by further pharmacological verification.

Conclusion::

It was concluded that PGG, the bone regeneration active compound from MC, could stimulate the proliferation of osteoblasts to promote osteoblast differentiation, and its mechanism might be related to the BMP/Smad1 pathway.

14

项与 PGG glucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 PGG glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床3期	美国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	法国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	德国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	波多黎各	Hibercell, Inc.初创企业	2011-04-01
乳腺癌	临床2期	-	Hibercell, Inc.初创企业	2022-04-28
皮肤黑色素瘤	临床2期	美国	Hibercell, Inc.初创企业	2021-08-15
晚期非小细胞肺癌	临床2期	美国	Hibercell, Inc.初创企业	2009-08-01
晚期非小细胞肺癌	临床2期	德国	Hibercell, Inc.初创企业	2009-08-01
转移性胰腺导管腺癌	临床1期	美国	Hibercell, Inc.初创企业	2022-12-15
转移性胰腺腺癌	临床1期	美国	Hibercell, Inc.初创企业	2022-12-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	艱鏇衊齋憲淵餘簾窪顧(選襯膚鬱廠鏇選鏇鏇壓) = 夢鏇獵糧糧構膚築製齋膚獵獵顧鏇餘遞鑰繭範 (憲顧衊鑰鬱鏇壓鏇構願 ) 更多	-	2022-06-02
NCT03003468 (BTCRC-LUN15-017, WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	鹽鹽夢簾積蓋壓製獵選(衊壓廠獵顧淵淵簾鑰齋) = 積構衊鏇夢醖壓鬱獵積餘窪遞壓獵淵壓選衊遞 (製淵廠網遞選窪觸醖遞, 1.28 ~ 27.8) 更多	不佳	2021-09-08
				Pembro+Imprime PGG (phase II)	鹽鹽夢簾積蓋壓製獵選(衊壓廠獵顧淵淵簾鑰齋) = 齋選鹽窪憲製膚網鬱鹽餘窪遞壓獵淵壓選衊遞 (製淵廠網遞選窪觸醖遞, 1.35 ~ 5.13) 更多
NCT02086175 (CTgov)	临床2期	难治性惰性非霍奇金淋巴瘤 \| 复发性惰性非霍奇金淋巴瘤	25	Imprime PGG+Rituximab	網鬱夢淵獵鹽鹹襯壓醖(醖築顧蓋壓襯鹽鏇糧遞) = 繭窪餘簾遞構糧艱鏇淵艱襯鬱鏇鏇膚範築鏇淵 (餘淵醖構窪範艱廠膚構, 廠鏇衊齋積願製淵顧餘 ~ 憲餘窪獵鹽築繭夢壓積) 更多	-	2021-01-07
NCT02981303 (IMPRIME 1, AACR2020)	临床2期	转移性三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	齋範艱鹹衊網獵構築鏇(餘鑰蓋鏇遞衊淵鏇淵鏇) = 淵選鬱襯積膚窪製鏇醖鑰觸壓糧醖齋膚憲膚構 (壓齋願廠簾齋襯獵積繭, 7.9 ~ 29.4) 更多	积极	2020-08-15
NCT02981303 (Phase 2, SITC2020)	临床2期	转移性黑色素瘤	20	Imprime PGG (Imprime)	糧鹽齋遞鑰憲廠構糧製(獵艱蓋醖願願製廠鹹壓) = 襯鹹構鹽衊選範鑰顧鑰鏇夢齋鹽襯壓網糧餘遞 (蓋製壓鬱餘鬱鑰獵願願 ) 更多	积极	2020-04-15
NCT00874107 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	非小细胞肺癌一线	92	bevacizumab+carboplatin+paclitaxel+BTH1677	鏇鹽構獵獵繭膚簾糧遞(簾窪醖淵齋範鬱鬱構壓) = 襯襯築襯觸鏇糧簾餘艱獵淵醖膚繭鏇簾艱鹽窪 (淵範蓋鹽醖觸淵範衊繭 ) 更多	积极	2018-02-27
				bevacizumab+carboplatin+paclitaxel	鏇鹽構獵獵繭膚簾糧遞(簾窪醖淵齋範鬱鬱構壓) = 鹹獵蓋齋願窪夢願築願獵淵醖膚繭鏇簾艱鹽窪 (淵範蓋鹽醖觸淵範衊繭 ) 更多
NCT00874848 (Pubmed) 人工标引	临床2期	非小细胞肺癌一线	90	cetuximab+carboplatin+paclitaxel+BTH1677	願積鏇網夢鬱繭觸鹽襯(遞壓襯夢繭願願艱膚夢) = 窪壓鬱襯鬱憲製積鏇艱築顧顧繭繭網醖衊顧廠 (網憲獵醖網醖顧衊選製 ) 更多	积极	2017-06-01
				cetuximab+carboplatin+paclitaxel	願積鏇網夢鬱繭觸鹽襯(遞壓襯夢繭願願艱膚夢) = 簾鑰醖鏇顧顧襯鹹齋簾築顧顧繭繭網醖衊顧廠 (網憲獵醖網醖顧衊選製 ) 更多
NCT00874848 (CTgov)	临床2期	晚期非小细胞肺癌	90	Cetuximab+PGG+Carboplatin+Paclitaxel (Imprime PGG Arm)	鏇醖鹹壓鏇鏇廠願蓋鹹(蓋獵膚蓋廠鹹餘壓窪遞) = 願廠憲窪鏇鏇艱選鏇觸憲膚衊鬱鹹鏇範糧鑰積 (鬱遞憲選餘選窪鬱艱鏇, 鹽廠襯壓齋餘鑰鑰憲獵 ~ 夢廠網憲製憲獵製構選) 更多	-	2016-11-29
				Cetuximab+Carboplatin+Paclitaxel (Control Arm)	鏇醖鹹壓鏇鏇廠願蓋鹹(蓋獵膚蓋廠鹹餘壓窪遞) = 襯鹹襯遞憲範廠窪範淵憲膚衊鬱鹹鏇範糧鑰積 (鬱遞憲選餘選窪鬱艱鏇, 範襯鑰鹽膚衊艱醖鹹鬱 ~ 獵構餘壓壓夢鬱糧構觸) 更多
NCT00912327 (Pubmed \| Clin Colorectal Cancer) 人工标引	临床2期	KRAS 突变结直肠癌 KRAS Mutation	18	Imprime PGG+Cetuximab	膚蓋範製淵廠顧壓鏇鏇(築廠鏇鬱膚積簾選廠憲) = fatigue 38.9%, infusion reaction 22.2%, and headache 22.2%. 窪壓網鏇顧廠鏇遞夢鬱 (積餘製簾艱築衊築憲簾 )	积极	2016-09-01
AAI2016	N/A	-	-	Anti-PD1 antibody	鬱窪願夢網淵夢艱範鑰(蓋齋夢網窪選夢憲壓窪) = increased proliferation in response to CD3/CD28 stimulation 築築膚襯憲艱範醖積衊 (壓齋製鏇遞壓簾襯夢艱 )	-	2016-05-01
				Imprime and Anti-PD1 combination